Abarelix

GnRH agonists such as leuprolide first stimulate the receptor before downregulating it, which produces a testosterone flare over the first one to two weeks — dangerous in men with spinal cord compromise or severe urinary obstruction. Abarelix instead antagonises the receptor from the first dose, so LH, FSH and testosterone fall within days with no flare and no need for antiandrogen cover. Castrate testosterone, under 50 ng/dL, was typically reached by day 8. The problem was immunological: abarelix caused immediate-onset systemic allergic reactions, including hypotension and syncope, at a cumulative rate that rose with continued exposure to roughly 3 to 4 percent by 15 months, requiring 30-minute post-injection observation for every dose. Degarelix, a later GnRH antagonist without that liability, superseded it entirely.

Targets: GnRH receptor (pituitary gonadotroph), LH and FSH secretion, Testicular testosterone production

• · 100 mg per injection. Mandatory post-dose observation was the practical reason clinics abandoned it, on top of the allergic reaction risk itself.

Work out your exact syringe units →

• very commonHot flushes— Universal to androgen deprivation, not specific to abarelix.
• very commonSleep disturbance
• very commonLoss of bone mineral density— The long-term cost of any sustained androgen deprivation.
• commonBreast enlargement and nipple tenderness
• commonQT prolongation— A class effect of androgen deprivation therapy generally.
• commonElevated liver transaminases
• uncommonImmediate-onset systemic allergic reaction— Hypotension, syncope, urticaria — cumulative incidence rising to roughly 3 to 4 percent with continued dosing. This is why the drug is gone.

• Any prior allergic reaction to abarelix — reactions recur and escalate.
• Settings without immediate access to resuscitation, since reactions were immediate-onset.
• Women and children — it was licensed only for men with advanced symptomatic prostate cancer unsuitable for other hormonal therapy.

• cautionOther QT-prolonging drugs — Additive repolarisation risk on top of the androgen deprivation effect itself.
• redundantDegarelix — Degarelix is the modern GnRH antagonist that does the same job without the allergic reaction profile.
• redundantGnRH agonists such as leuprolide — Same endpoint by a different route; the antagonist's selling point was avoiding the agonist flare.

• · Serum testosterone to confirm and maintain castrate levels.
• · PSA every 3 months.
• · Thirty minutes of direct observation after every injection, which was a labelled requirement.
• · Liver enzymes and ECG periodically.
• · Bone density on long-term androgen deprivation.

Withdrawn. Not marketed in the US since 2005 and not available elsewhere; it exists now as a historical reference point for the GnRH antagonist class.

• Trachtenberg et al. 2002, abarelix versus leuprolide plus bicalutamide in prostate cancer, Journal of Urology (trial)
• FDA prescribing information for Plenaxis (withdrawn product) (label)

The whole point of a GnRH antagonist is what it does not do. GnRH agonists like leuprolide bind the pituitary gonadotroph receptor and activate it, producing a surge of LH and FSH and a testosterone flare over the first one to two weeks before receptor downregulation and desensitisation eventually shut the axis down. That flare is not a curiosity — in a man with spinal metastases threatening cord compression, or severe bladder outlet obstruction, a testosterone surge can be catastrophic, which is why agonists are covered with an antiandrogen for the first weeks. Abarelix's structure is engineered to occupy the receptor without activating it. The five D-amino acid substitutions and the N-methylated tyrosine at position 5 disrupt the conformational change required for Gq coupling while preserving binding, so the receptor is occupied and silent. LH and FSH fall immediately, testicular testosterone production collapses, and castrate levels below 50 ng/dL are reached in most men by day 8 — compared with three to four weeks for an agonist. The failure was immunological, and it is worth being precise about it. Abarelix caused immediate-onset systemic allergic reactions with hypotension and syncope, and the cumulative incidence rose with continued exposure to roughly 3 to 4 percent by 15 months. Rising cumulative incidence with repeated dosing is the signature of an acquired immune response rather than a first-dose pharmacological effect, and it is generally attributed to a combination of anti-drug antibody formation and direct histamine release from the cationic peptide. Every dose required 30 minutes of observation. Degarelix, a later GnRH antagonist with different substitutions, achieves the same rapid castration without that liability, and it superseded abarelix entirely. The molecule remains a good teaching case for how a real pharmacological advantage can be defeated by an immunogenicity problem that only appears with cumulative exposure.

It went wrong in exactly one way, and it was enough. Immediate-onset systemic allergic reactions — hypotension, syncope, urticaria — with a cumulative incidence rising to roughly 3 to 4 percent by 15 months of therapy. The cumulative pattern is the important detail: this was not a first-dose idiosyncratic reaction that could be screened for, it was a risk that grew with exposure, which meant every patient on long-term therapy was walking towards it. The mitigation was 30 minutes of directly observed post-injection monitoring for every dose, indefinitely, which turned a simple monthly injection into a clinic appointment with staffing implications. Combined with a restricted distribution programme, that made the product commercially unviable, and it was voluntarily withdrawn from the US market in 2005. Degarelix delivered the same rapid flare-free castration without the reaction profile and took the indication. The general lesson is worth extracting: abarelix's pharmacology was better than the agonists it competed with, and pharmacology alone did not save it. Beyond that, everything else about it is the ordinary cost of androgen deprivation — hot flushes, sleep disturbance, gynaecomastia, bone loss, insulin resistance, mood change — which is universal to the approach rather than specific to this molecule.

1. 100 mgDay 1 — 100 mg, which is 100,000 micrograms, by deep gluteal intramuscular injection, followed by 30 minutes of direct observation. That observation requirement applied to every dose and was the practical reason clinics abandoned the product.
2. 100 mgDay 15 — Second loading dose. The two-week interval between the first three doses is what produces the rapid, sustained suppression.
3. 100 mgDay 29 and every 4 weeks thereafter — Maintenance. Testosterone was checked before each dose from day 29 onward, and failure to achieve castration was a reason to stop. The product is no longer marketed, so this ladder is historical.

• GnRH receptor on pituitary gonadotrophs — High-affinity competitive antagonism; the specific published constants are not readily accessible for a withdrawn product

  Immediate blockade of endogenous GnRH pulses with no receptor activation, so LH and FSH fall within hours and there is no flare.

• Luteinising hormone secretion — Downstream of receptor blockade

  Suppressed within days, which is the proximate cause of the testosterone collapse.

• Follicle-stimulating hormone secretion — Downstream of receptor blockade

  Suppressed more completely than with agonists, which is a consistent finding across the antagonist class.

• Testicular Leydig cell testosterone production — Downstream of LH suppression

  Castrate testosterone below 50 ng/dL in most men by day 8, versus three to four weeks for an agonist.

• Mast cell histamine release, plus acquired anti-drug immune response

  The immediate-onset systemic allergic reactions whose cumulative incidence rose to roughly 3 to 4 percent by 15 months. This is why the drug is not on the market.

• Phase 3 abarelix versus leuprolide plus daily antiandrogen Phase 3, multicentre, open-label, randomised · 2002

  Avoidance of testosterone surge and speed of medical castration in men with prostate cancer. Abarelix achieved castrate testosterone faster and without the agonist flare; it did not demonstrate a survival advantage.

LH and FSH fall within hours of the first injection. Testosterone falls within 1 to 3 days and reaches castrate levels below 50 ng/dL in most men by day 8, which is the number that made this class attractive — an agonist takes three to four weeks and goes the wrong way first. Hot flushes typically begin within the first two to four weeks as testosterone bottoms out. Bone loss and metabolic change accrue over months to years. The allergic reactions, when they came, were immediate-onset within the 30-minute observation window, and their cumulative risk climbed across the first 15 months of therapy.

The defining feature of a GnRH antagonist is that it needs no antiandrogen cover. Agonists require bicalutamide or a similar agent for the first two to four weeks specifically to blunt the flare; abarelix, having no flare, did not, and that was a genuine simplification. It could not be combined with a GnRH agonist — same axis, opposing pharmacology at the receptor, no rationale. The additive-risk list was anything else that prolongs the QT interval, on top of the QT effect that androgen deprivation produces on its own. The management that should accompany any sustained androgen deprivation applies here in full and is more important than most people treat it as: calcium, vitamin D, resistance exercise, a bone density scan at baseline, and a bisphosphonate or denosumab if the T-score warrants it. Metabolic monitoring for insulin resistance and dyslipidaemia belongs in the same package. None of this is abarelix-specific, and all of it is more consequential to a man's long-term health than the choice between agonist and antagonist.

Against leuprolide and the other GnRH agonists, abarelix's advantage was real and measurable: castrate testosterone by day 8 rather than three to four weeks, no flare, and no need for antiandrogen cover. It never demonstrated a survival advantage, which is worth saying plainly — faster castration is a mechanistic advantage, not automatically a clinical one. Against degarelix, the modern injectable GnRH antagonist, abarelix loses on every axis that matters: degarelix achieves the same rapid flare-free castration with a manageable local injection-site reaction profile and no cumulative systemic allergic risk, and it is still on the market. Against relugolix, the oral GnRH antagonist approved in 2020, the comparison is even more one-sided — a daily tablet with rapid castration, faster testosterone recovery on stopping and a lower reported cardiovascular event rate. Abarelix is the first-generation attempt whose successors solved its problem. Against the rest of this oncology class, it is the entry that best illustrates that being first and being pharmacologically superior are not the same as surviving.

Not applicable. The product has not been marketed since 2005 and there is no current price anywhere. It exists in this catalogue as a historical reference point for the GnRH antagonist class.

• ?Volume of distribution, clearance and elimination route are not available for a product withdrawn in 2005, and are left null rather than estimated from the GnRH antagonist class.
• ?The 97 percent protein binding figure is quoted from a secondary source reporting a 96 to 99 percent range and was not confirmed against a primary study or the original label in this session.
• ?Tmax after the intramuscular depot is not reported in accessible sources.
• ?GnRH receptor binding affinity constants are not quoted because I could not resolve them for this molecule.
• ?The Trachtenberg 2002 trial enrolment is left null because I resolved the publication record but not the participant count.
• ?The relative contribution of anti-drug antibodies versus direct mast cell degranulation to the systemic allergic reactions is not established.
• ?The apparent 13-day half-life describes depot release rather than the peptide's intrinsic elimination, and the intrinsic half-life is not separately reported.
• ?Accumulation is marked true because the four-weekly depot schedule produces sustained exposure, but no formal accumulation ratio is published.

• A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer Trachtenberg J, Gittleman M, Steidle C, et al., The Journal of Urology, 2002 · PMID 11912385

  The pivotal comparison against an agonist plus antiandrogen. Establishes the no-flare, faster-castration claim that was the drug's entire rationale.

• Abarelix — chemical structure and identity record PubChem, National Center for Biotechnology Information, PubChem compound record

  Source of the verified amino acid sequence with its D-substitutions and terminal modifications, the molecular formula C72H95ClN14O14 and the 1416.1 Da molecular weight.